Part 4/10:
McName emphasizes that the US’s significant investment in pharmaceutical innovation has benefited many countries. Much like how global defense advancements, driven heavily by American investments, benefit international allies, the US's advances in medication and healthcare technology hold similar value. This approach, he argues, underscores the importance of mutual cooperation rather than imposing rigid barriers, potentially opening pathways for negotiations that favor both nations.